Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma

In the current study, the use of oral lenalidomide monotherapy demonstrated clinically relevant efficacy among patients with systemic T-cell lymphomas. It appears to have excellent potential as an agent in combination therapy for patients with T-cell lymphoma.